BioCentury
ARTICLE | Clinical News

NGM Biopharmaceuticals preclinical data

May 11, 2015 7:00 AM UTC

In a mouse model of NASH, NGM282 significantly reduced total body weight, liver weight and liver-to-body weight ratio. NGM282 also significantly improved total non-alcoholic fatty liver disease (NAFLD...